Market Place
Sourcing Support
Spyre Therapeutics Begins Phase 1 Trial of SPY003 Antibody
27 Mar 2025 //
PR NEWSWIRE
Spyre Therapeutics to Present Poster at European Crohn`s Congress
19 Feb 2025 //
PR NEWSWIRE
Spyre Therapeutics Highlights 2025 Priorities And Pipeline Updates
13 Jan 2025 //
PR NEWSWIRE
Spyre Therapeutics Doses First Participants in Anti-TL1A Trial
02 Dec 2024 //
PR NEWSWIRE
Spyre Therapeutics Announces Positive Ph 1 Results for SPY001
12 Nov 2024 //
PR NEWSWIRE
Spyre Reports Q3 2024 Financials & Corporate Update
07 Nov 2024 //
PR NEWSWIRE
Spyre Therapeutics to Attend November Investor Conferences
30 Oct 2024 //
PR NEWSWIRE
Spyre Therapeutics Announces Acceleration Of SPY003 Timelines
14 Oct 2024 //
PR NEWSWIRE
Spyre Therapeutics Appoints Dr. Sheldon Sloan as CMO
01 Oct 2024 //
PR NEWSWIRE
Spyre Therapeutics to Participate in Upcoming Investor Conference
10 Sep 2024 //
PR NEWSWIRE
Spyre Therapeutics Doses First Participants In SPY001 Phase 1 Trial For IBD
18 Jun 2024 //
PR NEWSWIRE
Spyre Therapeutics Q1 2024 Financials, Corporate Update
09 May 2024 //
PR NEWSWIRE
Apogee, Spyre founder launches its third biotech and heads straight to Nasdaq
03 Apr 2024 //
ENDPTS
Spyre Therapeutics Announces $180 Million Private Placement
18 Mar 2024 //
PRESS RELEASE
Spyre Therapeutics Announces Grants of Inducement Awards
01 Mar 2024 //
PRESS RELEASE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.